We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information on the programme, including the screening tests, commissioning, quality assurance, education and training.
Training and continuing professional development for people working in the sickle cell and thalassaemia screening programme in England.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020
Guidance for healthcare professionals covering the pathway for sickle cell and thalassaemia screening.
Essential elements for implementation of the family origin questionnaire (FOQ) to help assess if a person is a likely carrier for sickle cell and thalassaemia (SCT).
Data reports, data collection templates and research application guidance for the NHS sickle cell and thalassaemia (SCT) screening programme.
Population screening programmes: NHS sickle cell and thalassaemia (SCT) screening programme. The latest pages tagged as SCT will appear here.
Advice for people who commission, fund, deliver and evaluate health outreach programmes.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).